Takeda R&D President Andy Plump and GV Managing Partner Krishna Yeshwant Announce Retirements

Takeda Pharmaceutical Company’s President of Research and Development, Andy Plump, and GV’s Managing Partner, Krishna Yeshwant, have announced their respective plans to retire. Both executives confirmed their departures this week, marking a significant leadership transition for the pharmaceutical and venture capital sectors.

Andy Plump concludes a tenure at Takeda during which he oversaw the company’s transition into a global research-driven organization. His leadership focused on restructuring the firm’s R&D pipeline and expanding its international presence. Simultaneously, Krishna Yeshwant prepares to step down from his role at GV, the venture capital arm of Alphabet Inc. Yeshwant managed a diverse portfolio of investments, contributing to the firm’s strategy in the life sciences and technology markets. Both organizations have begun the process of identifying successors to fill these leadership positions.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: September 11, 2026

Author

GOAI